NANOPARTICLE FORMULATIONS AND USES THEREOF
PROBLEM TO BE SOLVED: To provide nanoparticle formulations and use thereof.SOLUTION: The invention provides a composition comprising nanoparticles comprising 1) a drug (a hydrophobic drug derivative or the like) and 2) a carrier protein. The invention also provides a treatment method of a disease (c...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SHERRY XIAOPEI CI TAO CHUNLIN NEIL P DESAI VUONG TRIEU TAPAS DE |
| description | PROBLEM TO BE SOLVED: To provide nanoparticle formulations and use thereof.SOLUTION: The invention provides a composition comprising nanoparticles comprising 1) a drug (a hydrophobic drug derivative or the like) and 2) a carrier protein. The invention also provides a treatment method of a disease (cancer or the like) using the composition, a kit, and a unit dosage. In some embodiments, a nanoparticle comprises a hydrophobic taxane derivative and a carrier protein. In some embodiments, the carrier protein is albumin (human serum albumin or the like).In some embodiments, the average diameter of the nanoparticle in the composition herein is about 150 nm or less (for example, any one of about 100, 90, 80, 70, or 60 nm or less is comprised).SELECTED DRAWING: None
【課題】ナノ粒子処方物およびその使用の提供。【解決手段】本発明は、１）薬物（疎水性薬物誘導体など）および２）キャリアタンパク質を含むナノ粒子を含む組成物を提供する。前記組成物ならびにキットおよび単位投薬量を使用した疾患（癌など）の処置方法も提供する。いくつかの実施形態では、ナノ粒子は、疎水性タキサン誘導体およびキャリアタンパク質を含む。いくつかの実施形態では、キャリアタンパク質はアルブミン（ヒト血清アルブミンなど）である。いくつかの実施形態では、本明細書中に記載の組成物中のナノ粒子の平均直径は約１５０ｎｍ以下（例えば、約１００、９０、８０、７０、または６０ｎｍ以下のうちのいずれか１つが含まれる）である。【選択図】なし |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2017114913A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2017114913A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2017114913A3</originalsourceid><addsrcrecordid>eNrjZNDyc_TzD3AMCvF09nFVcPMP8g31cQzx9PcLVnD0c1EIDXYNVgjxcA1y9XfjYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBobmhoYmlobGjsZEKQIAsQIlQg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NANOPARTICLE FORMULATIONS AND USES THEREOF</title><source>esp@cenet</source><creator>SHERRY XIAOPEI CI ; TAO CHUNLIN ; NEIL P DESAI ; VUONG TRIEU ; TAPAS DE</creator><creatorcontrib>SHERRY XIAOPEI CI ; TAO CHUNLIN ; NEIL P DESAI ; VUONG TRIEU ; TAPAS DE</creatorcontrib><description>PROBLEM TO BE SOLVED: To provide nanoparticle formulations and use thereof.SOLUTION: The invention provides a composition comprising nanoparticles comprising 1) a drug (a hydrophobic drug derivative or the like) and 2) a carrier protein. The invention also provides a treatment method of a disease (cancer or the like) using the composition, a kit, and a unit dosage. In some embodiments, a nanoparticle comprises a hydrophobic taxane derivative and a carrier protein. In some embodiments, the carrier protein is albumin (human serum albumin or the like).In some embodiments, the average diameter of the nanoparticle in the composition herein is about 150 nm or less (for example, any one of about 100, 90, 80, 70, or 60 nm or less is comprised).SELECTED DRAWING: None
【課題】ナノ粒子処方物およびその使用の提供。【解決手段】本発明は、１）薬物（疎水性薬物誘導体など）および２）キャリアタンパク質を含むナノ粒子を含む組成物を提供する。前記組成物ならびにキットおよび単位投薬量を使用した疾患（癌など）の処置方法も提供する。いくつかの実施形態では、ナノ粒子は、疎水性タキサン誘導体およびキャリアタンパク質を含む。いくつかの実施形態では、キャリアタンパク質はアルブミン（ヒト血清アルブミンなど）である。いくつかの実施形態では、本明細書中に記載の組成物中のナノ粒子の平均直径は約１５０ｎｍ以下（例えば、約１００、９０、８０、７０、または６０ｎｍ以下のうちのいずれか１つが含まれる）である。【選択図】なし</description><language>eng ; jpn</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170629&DB=EPODOC&CC=JP&NR=2017114913A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170629&DB=EPODOC&CC=JP&NR=2017114913A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHERRY XIAOPEI CI</creatorcontrib><creatorcontrib>TAO CHUNLIN</creatorcontrib><creatorcontrib>NEIL P DESAI</creatorcontrib><creatorcontrib>VUONG TRIEU</creatorcontrib><creatorcontrib>TAPAS DE</creatorcontrib><title>NANOPARTICLE FORMULATIONS AND USES THEREOF</title><description>PROBLEM TO BE SOLVED: To provide nanoparticle formulations and use thereof.SOLUTION: The invention provides a composition comprising nanoparticles comprising 1) a drug (a hydrophobic drug derivative or the like) and 2) a carrier protein. The invention also provides a treatment method of a disease (cancer or the like) using the composition, a kit, and a unit dosage. In some embodiments, a nanoparticle comprises a hydrophobic taxane derivative and a carrier protein. In some embodiments, the carrier protein is albumin (human serum albumin or the like).In some embodiments, the average diameter of the nanoparticle in the composition herein is about 150 nm or less (for example, any one of about 100, 90, 80, 70, or 60 nm or less is comprised).SELECTED DRAWING: None
【課題】ナノ粒子処方物およびその使用の提供。【解決手段】本発明は、１）薬物（疎水性薬物誘導体など）および２）キャリアタンパク質を含むナノ粒子を含む組成物を提供する。前記組成物ならびにキットおよび単位投薬量を使用した疾患（癌など）の処置方法も提供する。いくつかの実施形態では、ナノ粒子は、疎水性タキサン誘導体およびキャリアタンパク質を含む。いくつかの実施形態では、キャリアタンパク質はアルブミン（ヒト血清アルブミンなど）である。いくつかの実施形態では、本明細書中に記載の組成物中のナノ粒子の平均直径は約１５０ｎｍ以下（例えば、約１００、９０、８０、７０、または６０ｎｍ以下のうちのいずれか１つが含まれる）である。【選択図】なし</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDyc_TzD3AMCvF09nFVcPMP8g31cQzx9PcLVnD0c1EIDXYNVgjxcA1y9XfjYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBobmhoYmlobGjsZEKQIAsQIlQg</recordid><startdate>20170629</startdate><enddate>20170629</enddate><creator>SHERRY XIAOPEI CI</creator><creator>TAO CHUNLIN</creator><creator>NEIL P DESAI</creator><creator>VUONG TRIEU</creator><creator>TAPAS DE</creator><scope>EVB</scope></search><sort><creationdate>20170629</creationdate><title>NANOPARTICLE FORMULATIONS AND USES THEREOF</title><author>SHERRY XIAOPEI CI ; TAO CHUNLIN ; NEIL P DESAI ; VUONG TRIEU ; TAPAS DE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2017114913A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2017</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHERRY XIAOPEI CI</creatorcontrib><creatorcontrib>TAO CHUNLIN</creatorcontrib><creatorcontrib>NEIL P DESAI</creatorcontrib><creatorcontrib>VUONG TRIEU</creatorcontrib><creatorcontrib>TAPAS DE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHERRY XIAOPEI CI</au><au>TAO CHUNLIN</au><au>NEIL P DESAI</au><au>VUONG TRIEU</au><au>TAPAS DE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NANOPARTICLE FORMULATIONS AND USES THEREOF</title><date>2017-06-29</date><risdate>2017</risdate><abstract>PROBLEM TO BE SOLVED: To provide nanoparticle formulations and use thereof.SOLUTION: The invention provides a composition comprising nanoparticles comprising 1) a drug (a hydrophobic drug derivative or the like) and 2) a carrier protein. The invention also provides a treatment method of a disease (cancer or the like) using the composition, a kit, and a unit dosage. In some embodiments, a nanoparticle comprises a hydrophobic taxane derivative and a carrier protein. In some embodiments, the carrier protein is albumin (human serum albumin or the like).In some embodiments, the average diameter of the nanoparticle in the composition herein is about 150 nm or less (for example, any one of about 100, 90, 80, 70, or 60 nm or less is comprised).SELECTED DRAWING: None
【課題】ナノ粒子処方物およびその使用の提供。【解決手段】本発明は、１）薬物（疎水性薬物誘導体など）および２）キャリアタンパク質を含むナノ粒子を含む組成物を提供する。前記組成物ならびにキットおよび単位投薬量を使用した疾患（癌など）の処置方法も提供する。いくつかの実施形態では、ナノ粒子は、疎水性タキサン誘導体およびキャリアタンパク質を含む。いくつかの実施形態では、キャリアタンパク質はアルブミン（ヒト血清アルブミンなど）である。いくつかの実施形態では、本明細書中に記載の組成物中のナノ粒子の平均直径は約１５０ｎｍ以下（例えば、約１００、９０、８０、７０、または６０ｎｍ以下のうちのいずれか１つが含まれる）である。【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2017114913A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | NANOPARTICLE FORMULATIONS AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A05%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHERRY%20XIAOPEI%20CI&rft.date=2017-06-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2017114913A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |